Formoterol hydrochloride | 1254710-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Formoterol hydrochloride
• 英文别名: N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrochloride
• CAS: 1254710-01-4
• 化学式: C19H25ClN2O4
• 分子量: 380.9
• InChiKey: VBOQGHUYFLYKOQ-QVRIGTRMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.65
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  90.8
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• New bicyclic compounds as crac channel modulators
  申请人：Almirall, S.A.

  公开号：EP2738172A1

  公开（公告）日：2014-06-04

  The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

  这项发明涉及一种新型化合物，它们是CRAC通道活性的抑制剂。该发明还涉及含有这些化合物的药物组合物，它们的制备方法以及它们在治疗中的应用。
• New pyrazole derivatives as CRAC channel modulators
  申请人：Almirall, S.A.

  公开号：EP2848615A1

  公开（公告）日：2015-03-18

  The present invention relates to compounds of formula (I) which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

  本发明涉及一种具有式(I)的化合物，它们是CRAC通道活性的抑制剂。本发明还涉及含有这些化合物的药物组合物、它们的制备过程以及它们在治疗中的应用。
• Pharmaceutical compositions containing an oxitropium salt and a betamimetic
  申请人：——

  公开号：US20020179087A1

  公开（公告）日：2002-12-05

  Pharmaceutical composition comprising: (a) an oxitropium salt; and (b) a betamimetic, and their use in treating inflammatory or obstructive diseases of the respiratory tract in a patient in need of such treatment.

  包含以下成分的药物组合物：(a) 一种氧托品盐；(b) 一种拟倍他命，以及它们在治疗需要此类治疗的患者的呼吸道炎症或阻塞性疾病中的用途。
• Pharmaceutical compositions containing an ipratropium salt and a betamimetic
  申请人：——

  公开号：US20020189610A1

  公开（公告）日：2002-12-19

  Pharmaceutical composition comprising: (a) an ipratropium salt; and (b) a betamimetic, and their use in treating inflammatory or obstructive diseases of the respiratory tract in a patient in need of such treatment.

  由以下成分组成的药物组合物：(a) 异丙托溴铵盐；(b) 拟贝特类药物，以及它们在治疗需要此类治疗的患者的呼吸道炎症或阻塞性疾病中的用途。
• Medicaments comprising betamimetics and a novel anticholinergic
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040010003A1

  公开（公告）日：2004-01-15

  A pharmaceutical composition comprising: (a) a salt of formula 1 1 wherein: X − is an anion with a single negative charge; and (b) a betamimetic 2, or a solvate or hydrate thereof, optionally in the form of the enantiomers, mixtures of the enantiomers, or in the form of the racemates thereof, processes for preparing them and their use in the treatment of respiratory complaints.

  一种药物组合物，包括 (a) 式 1 的盐 1 其中 X - 是带有单个负电荷的阴离子；以及 (b) betamimetic 2、 或其溶液或水合物，可选择以对映体、对映体混合物或其外消旋物的形式存在，以及制备它们的工艺和它们在治疗呼吸系统疾病中的用途。